Aurore Morello
Researcher at OSE Immunotherapeutics | Nantes, Pays de la Loire, France
Aurore Morello’s Email & Phone Number
VerifiedFree account · No credit card · 5 profiles/month
Researcher at OSE Immunotherapeutics in December 2016 - Present
Head of research, Director of R&D program at OSE Immunotherapeutics in October 2022 - Present
Postdoctoral Research Scholar at Memorial Sloan Kettering Cancer Center in November 2013 - December 2016
Postdoctoral Fellow and PhD student at CNRS UMR 5164 in September 2011 - April 2013
Université Victor Segalen (Bordeaux II), January 2009 to January 2012
Université de Rennes I, January 2004 to January 2007
OSE Immunotherapeutics, a biotech dedicated to developing first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). • Tedopi® (therapeutic cancer vaccine): Registration Phase 3 in 2nd-line NSCLC in HLA-A2+ patients with secondary resistance. Phase 2 trials, sponsored by onco groups, of Tedopi® in combo in solid tumors. • Lusvertikimab (mAb IL-7R antagonist); Positive Phase 2 in UC; preclinical research in ALL. • OSE-279 (anti-PD1): 1st positive results in Phase 1/2 in solid tumors. • FR-104/VEL-101 (anti-CD28 mAb): developed in partnership with Veloxis in transplant; Phase 1/2 in renal transplant (CHU Nantes); successful Phase 1 in the US (Veloxis). • Anti-SIRPα mAb developed in partnership with Boehringer Ingelheim in advanced solid tumors & cardiovascular-renal-metabolic diseases; positive Phase 1 dose escalation results in monotherapy and combo; Phase 2 in CRM diseases planned end 2024. • ABBV-230 (ChemR23 agonist mAb) developed in partnership with AbbVie in chronic inflammation. 4 proprietary drug discovery platforms • Pro-resolutive mAb platform • Myeloid Checkpoint platform • BiCKI® Platform • mRNA Therapeutic platform f
Discover more about OSE Immunotherapeutics
Director of Clinical Operations at OSE Immunotherapeutics
Director Clinical Operations at OSE Immunotherapeutics
(August 2020 – Present)
Directeur Administratif et Financier chez OSE Immunotherapeutics
Chief Financial Officer at OSE Immunotherapeutics
(June 2016 – Present)
Antibody Discovery Manager chez OSE Immunotherapeutics
Antibody Discovery Manager at OSE Immunotherapeutics
(January 2024 – Present)
PhD Student at OSE Immunotherapeutics
PhD Student at OSE Immunotherapeutics
(December 2021 – Present)
Actuellement en 6e année de Pharmacie à la Faculté de Toulouse et en 2e année à l'ENSTBB à Bordeaux
Stagiaire chargé d'assurance qualité at Servier
(March 2023 – Present)
Director Clinical Operations - chez Onward Therapeutics
Clinical Project Director - Early phase studies / Immuno-onco at OSE Immunotherapeutics
(March 2021 – Present)
What is Aurore Morello email address?
Email Aurore Morello at [email protected] and [email protected]. This email is the most updated Aurore Morello's email found in 2026.
How to contact Aurore Morello?
To contact Aurore Morello send an email to [email protected] or [email protected].
What company does Aurore Morello work for?
Aurore Morello works for OSE Immunotherapeutics.
What is Aurore Morello's role at OSE Immunotherapeutics?
Aurore Morello is Researcher
What industry does Aurore Morello work in?
Aurore Morello works in the Research industry.
